{"id":839251,"date":"2025-04-21T06:33:20","date_gmt":"2025-04-21T10:33:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/"},"modified":"2025-04-21T06:33:20","modified_gmt":"2025-04-21T10:33:20","slug":"affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/","title":{"rendered":"Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">MANNHEIM, Germany, April  21, 2025  (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the \u201cNotice\u201d), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company\u2019s common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the \u201cMinimum Bid Price Rule\u201d).<\/p>\n<p>In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until October 13, 2025, to regain compliance. If the Company fails to regain compliance with the Minimum Bid Price Rule during this period, the Company may consider applying to transfer its securities from The Nasdaq Global Select Market to The Nasdaq Capital Market, provided that the Company meets the applicable market value of publicly held shares required for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the bid price requirement). Such transfer would provide the Company with an additional 180 calendar days, or until April 13, 2025, to regain compliance. There can be no assurance that the Company would be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq staff would grant the Company\u2019s request for continued listing.<\/p>\n<p>The Notice has no immediate effect on the listing or trading of the Company\u2019s common shares.<\/p>\n<p>The Company intends to monitor the bid price of its common shares and consider available options to regain compliance with the Minimum Bid Price Rule.<\/p>\n<p>\n        <strong>About Affimed N.V. <\/strong>\n      <\/p>\n<p>Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company\u2019s innate cell engagers (ICE<sup>\u00ae<\/sup>) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE<sup>\u00ae<\/sup>\u00a0are generated on the Company\u2019s proprietary ROCK<sup>\u00ae<\/sup>\u00a0platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE<sup>\u00ae<\/sup>\u00a0molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients\u2019 lives. For more about the Company\u2019s people, pipeline and partners, please visit:\u00a0<u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=unPeIjWMGUpuN8AA8h6RIxPSD0M765KxE9_zGEO7gK8uQL2g6oWPQ-afPh2f-c5EWP_UH9C8YwX9ZofB0A_KPQ==\" rel=\"nofollow\" target=\"_blank\">www.affimed.com<\/a><\/u>.<\/p>\n<p>\n        <strong>FORWARD-LOOKING STATEMENTS <\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201clook forward to,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions. Forward-looking statements include, among other things, statements regarding the Company\u2019s compliance with the Minimum Bid Price Rule and listing or trading of the Company\u2019s common shares. Actual results may differ materially from the results anticipated by the Company\u2019s forward-looking statements due to certain risks, uncertainties and other factors described under the heading \u201cRisk Factors\u201d in the Company\u2019s filings with the Securities and Exchange Commission. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.<\/p>\n<p>\n        <strong>Investor Relations Contact <\/strong><br \/>\n        <br \/>Alexander Fudukidis <br \/>Director, Investor Relations <br \/>E-Mail: <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VUVCYhp6tlUzSwdVhBYo3HJdzUyVRQ59_T--ObBgMD6IkPqA5M6AdmlrMq6fILgm2M4t9g2EN-01p-C81Dx6DMh11-tx6jerba_6ZhDtADA=\" rel=\"nofollow\" target=\"_blank\">a.fudukidis@affimed.com<\/a><\/u><br \/>Tel.: +1 (917) 436-8102<\/p>\n<p>\n        <strong>Media Contact <\/strong><br \/>\n        <br \/>Mary Beth Sandin <br \/>Vice President, Marketing and Communications <br \/>E-Mail: <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=anfic1wUKIIsigcC6R59RUiHubS8HawoN2Z4a7qpRnJP9lse0YqCZFxT6NaUwZSoLD2wXojz54vXsHuwtX3D8c1NkDPrh5MIF2mJQDA7iuM=\" rel=\"nofollow\" target=\"_blank\">m.sandin@affimed.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNTM1MSM2ODk1MDY3IzIwMDM3MzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjhjNDM5ZTQtZTM2YS00OGRhLWIyNzItOWNlMTRjZjlkNTU2LTEwMTUzMDctMjAyNS0wNC0yMS1lbg==\/tiny\/Affimed-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the \u201cNotice\u201d), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company\u2019s common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the \u201cMinimum Bid Price Rule\u201d). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until October 13, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-839251","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the \u201cNotice\u201d), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company\u2019s common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the \u201cMinimum Bid Price Rule\u201d). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until October 13, &hellip; Continue reading &quot;Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-21T10:33:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNTM1MSM2ODk1MDY3IzIwMDM3MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement\",\"datePublished\":\"2025-04-21T10:33:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\\\/\"},\"wordCount\":620,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNTM1MSM2ODk1MDY3IzIwMDM3MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\\\/\",\"name\":\"Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNTM1MSM2ODk1MDY3IzIwMDM3MzQ=\",\"datePublished\":\"2025-04-21T10:33:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNTM1MSM2ODk1MDY3IzIwMDM3MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNTM1MSM2ODk1MDY3IzIwMDM3MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/","og_locale":"en_US","og_type":"article","og_title":"Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk","og_description":"MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the \u201cNotice\u201d), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company\u2019s common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the \u201cMinimum Bid Price Rule\u201d). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until October 13, &hellip; Continue reading \"Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-21T10:33:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNTM1MSM2ODk1MDY3IzIwMDM3MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement","datePublished":"2025-04-21T10:33:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/"},"wordCount":620,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNTM1MSM2ODk1MDY3IzIwMDM3MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/","name":"Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNTM1MSM2ODk1MDY3IzIwMDM3MzQ=","datePublished":"2025-04-21T10:33:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNTM1MSM2ODk1MDY3IzIwMDM3MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNTM1MSM2ODk1MDY3IzIwMDM3MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/839251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=839251"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/839251\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=839251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=839251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=839251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}